Supplementary materials: Healthcare costs and resource utilization of patients with chronic post-traumatic stress disorder: a retrospective US claims analysis of commercially insured patients

These are peer-reviewed supplementary materials for the article 'Healthcare costs and resource utilization of patients with chronic post-traumatic stress disorder: a retrospective US claims analysis of commercially insured patients' published in the Journal of Comparative Effectiveness Research.Table A1: ICD-10-CM codes for chronic PTSDTable A2: ICD-10 CM codes for acute PTSDTable A3: ICD-10-CM codes related to cancer diagnosisTable A4: ICD-10-CM codes related to MDD, bipolar disorder, and schizophreniaTable A5: NDC codes related to FDA-approved medications for PTSD treatmentTable A6: Procedure codes related to the psychotherapies used for PTSD managementTable A7: ICD-10-CM codes related to anxietyTable A8: Demographic characteristics of the matched populationTable A9: Clinical characteristics of the matched populationTable A10: Out-of-pocket healthcare costs of PTSD patients during the 2-year follow-up period within the matched populationTable A11: Overall healthcare costs of PTSD patients during the 2-year follow-up period within the matched populationTable A12: The resource use of PTSD patients during the first year of the follow-up period within the matched populationTable A13: Demographic characteristics of PTSD patients with SUD/AUD diagnosisTable A14: Clinical characteristics of PTSD patients with SUD/AUD diagnosisTable A15: Out-of-pocket healthcare costs of PTSD during the 2-year follow-up period within the sub-sample of patients diagnosed with SUD/AUDTable A16: Overall healthcare costs of PTSD during the 2-year follow-up period within the sub-sample of patients diagnosed with SUD/AUDTable A17: Resource use during the first year of the follow-up period within the sub-sample of chronic PTSD patients diagnosed with SUD/AUDAim: Exploring the healthcare costs and resource use among privately insured US patients with posttraumatic stress disorder (PTSD). Methods: This study used Merative MarketScan data. The index date was defined as the first PTSD claim. Study period included a 1-year pre-index and 2-year post-index follow-up. Cases with only acute PTSD, cancer, or insurance gap during the study period were excluded. The PTSD with (PwC) and PTSD without comorbidities (PwoC) cohorts were defined by the presence/absence of comorbid mental health conditions (schizophrenia, bipolar and major depressive disorder). Baseline PTSD (BP) cohort included PwoC cases with only index PTSD event and without FDA-approved PTSDmedications or psychotherapy. Sub-analysis is conducted among patients with PTSD and substance/alcohol use disorder. Study cohorts were matched in a 1:1:1 ratio. Results: The matched sample included 5076 patients (1681 PwC, 1681 PwoC, 1714 BP). PwC patients had higher 2-year PTSD-related costs than PwoC and BP patients ($3762 vs $1750 and $841; all p < 0.001). The same trend was noted among all-cause and anxiety-related costs. PwC patients had higher 2-year PTSD-related inpatient and emergency department (ED) rates than PwoC (10.2% vs 1.7% and 6.8% vs 2.6%, all p < 0.001) and inpatient and outpatient rates than BP (10.2% vs 2.1% and 98.0% vs 93.1%; all p ≤ 0.004). The sub-analysis had 3776 patients (3154 PwC, 537 PwoC, 85 BP). PwC had higher 2-year PTSD-related costs than PwoC and BP ($7668 vs $2919 and $1,483; all p < 0.001). The same trend was noted in all-cause and anxiety-related costs. PwC also had higher 2-year PTSD-related inpatient and ED rates than PwoC (25.6% vs 10.4% and 12.7% vs 5.2%; all p < 0.001) and inpatient and outpatient rates than BP (25.6% vs 8.2% and 95.5% vs 84.7%; all p < 0.001). Conclusion: PTSD is associated with high healthcare costs and resource use. The highest economic burden was observed in patients with PTSD and mental health comorbidities.

本数据集为发表于《比较效果研究杂志》的论文《慢性创伤后应激障碍患者医疗费用及资源利用率：一项针对商业保险患者的美国回顾性索赔分析》的同行评审补充材料。表 A1：慢性创伤后应激障碍的 ICD-10-CM 编码表 A2：急性创伤后应激障碍的 ICD-10 CM 编码表 A3：与癌症诊断相关的 ICD-10-CM 编码表 A4：与重度抑郁症、双相情感障碍和精神分裂症相关的 ICD-10-CM 编码表 A5：与 FDA 批准的 PTSD 治疗药物相关的 NDC 编码表 A6：用于 PTSD 管理的心理治疗相关程序编码表 A7：与焦虑相关的 ICD-10-CM 编码表 A8：匹配人群的人口统计学特征表 A9：匹配人群的临床特征表 A10：匹配人群中 PTSD 患者在两年随访期间的自行承担的医疗费用表 A11：匹配人群中 PTSD 患者在两年随访期间的总体医疗费用表 A12：匹配人群中 PTSD 患者在随访第一年的资源利用率表 A13：患有精神活性物质使用障碍/酒精使用障碍的 PTSD 患者的人口统计学特征表 A14：患有精神活性物质使用障碍/酒精使用障碍的 PTSD 患者的临床特征表 A15：在患有精神活性物质使用障碍/酒精使用障碍的亚样本中，PTSD 患者在两年随访期间的自行承担的医疗费用表 A16：在患有精神活性物质使用障碍/酒精使用障碍的亚样本中，PTSD 患者在两年随访期间的总体医疗费用表 A17：在慢性 PTSD 患者亚样本中，随访第一年的资源利用率。研究目的：探究美国私营保险患者中创伤后应激障碍（PTSD）患者的医疗费用及资源利用情况。研究方法：本研究采用 Merative MarketScan 数据。索引日期定义为首次 PTSD 索赔日期。研究期间包括索引日期前一年的随访和索引日期后两年的随访。在研究期间仅患有急性 PTSD、癌症或保险中断的患者被排除在外。通过存在/不存在合并的精神健康疾病（精神分裂症、双相情感障碍和重度抑郁症）来定义 PTSD 伴合并症（PwC）和 PTSD 无合并症（PwoC）队列。基线 PTSD（BP）队列包括仅发生索引 PTSD 事件且未接受 FDA 批准的 PTSD 药物或心理治疗的 PwoC 案例子集。在 PTSD 和物质/酒精使用障碍患者中进行亚组分析。研究队列以 1:1:1 的比例进行匹配。研究结果：匹配样本包括 5076 名患者（1681 名 PwC，1681 名 PwoC，1714 名 BP）。PwC 患者的两年 PTSD 相关费用高于 PwoC 和 BP 患者（3762 美元 vs 1750 美元和 841 美元；所有 p < 0.001）。这一趋势在所有原因相关和焦虑相关费用中也得到体现。PwC 患者的两年 PTSD 相关住院和急诊（ED）比率高于 PwoC（10.2% vs 1.7% 和 6.8% vs 2.6%，所有 p < 0.001），以及住院和门诊比率高于 BP（10.2% vs 2.1% 和 98.0% vs 93.1%；所有 p ≤ 0.004）。亚组分析包括 3776 名患者（3154 名 PwC，537 名 PwoC，85 名 BP）。PwC 的两年 PTSD 相关费用高于 PwoC 和 BP 患者（7668 美元 vs 2919 美元和 1483 美元；所有 p < 0.001）。这一趋势在所有原因相关和焦虑相关费用中也得到体现。PwC 的两年 PTSD 相关住院和 ED 比率也高于 PwoC（25.6% vs 10.4% 和 12.7% vs 5.2%；所有 p < 0.001），以及住院和门诊比率高于 BP（25.6% vs 8.2% 和 95.5% vs 84.7%；所有 p < 0.001）。结论：PTSD 与高昂的医疗费用和资源利用相关。在患有 PTSD 且合并精神健康疾病的患者中观察到最高的经济负担。